---
title: "Silo Pharma, Inc. (SILO.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/SILO.US.md"
symbol: "SILO.US"
name: "Silo Pharma, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T07:12:03.955Z"
locales:
  - [en](https://longbridge.com/en/quote/SILO.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/SILO.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/SILO.US.md)
---

# Silo Pharma, Inc. (SILO.US)

## Company Overview

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [ilopharma.com](https://ilopharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:13.000Z

**Overall: D (0.62)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 315 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% |  |
| Net Profit YoY | -4.77% |  |
| P/B Ratio | 1.07 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 6067439.19 |  |
| Revenue | 72102.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -99.94% | E |
| Profit Margin | -6717.40% | E |
| Gross Margin | -14.77% | E |
| Revenue YoY | 0.00% | D |
| Net Profit YoY | -4.77% | C |
| Total Assets YoY | 18.95% | A |
| Net Assets YoY | 41.65% | A |
| Cash Flow Margin | 79.36% | C |
| OCF YoY | 0.00% | D |
| Turnover | 0.01 | E |
| Gearing Ratio | 19.04% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Silo Pharma, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-4.77%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.07",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "6067439.19",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "72102.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-99.94%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-6717.40%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-14.77%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-4.77%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "18.95%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "41.65%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "79.36%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.01",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "19.04%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.25 | 198/386 | - | - | - |
| PB | 1.07 | 101/386 | 1.30 | 1.11 | 0.94 |
| PS (TTM) | 84.15 | 249/386 | 92.12 | 71.17 | 61.54 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2023-11-21T05:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Overweight | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.37 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/SILO.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/SILO.US/norm.md)
- [Related News](https://longbridge.com/en/quote/SILO.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/SILO.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**